DOT Drug Testing for Cannabis — 49 CFR Part 40

The Department of Transportation regulates drug testing for millions of safety-sensitive transportation workers under 49 CFR Part 40. DOT testing for cannabis is unaffected by state legalization — DOT treats marijuana as a Schedule I controlled substance regardless of whether state law says otherwise. A state medical cannabis card provides zero protection for DOT-regulated workers.

Who Is Subject to DOT Testing?

• CDL holders (Commercial Driver's License) — the largest group; millions of truck and bus drivers
• Pilots (FAA)
• Flight attendants and aircraft maintenance personnel (FAA)
• Air traffic controllers (FAA)
• Railroad workers (FRA) — engineers, conductors, dispatchers, maintenance
• Pipeline workers (PHMSA)
• Transit operators (FTA) — bus drivers, train operators, and mechanics
• Merchant mariners (USCG)

If your job falls into any of these categories, federal rules apply regardless of your state of residence or the state in which you perform your duties.

The Six Testing Categories

DOT employers must conduct drug testing under six circumstances:

1. Pre-employment — before starting safety-sensitive duties
2. Random — unannounced testing on a statistical basis (50% annual rate for drugs in most DOT modes)
3. Post-accident — after certain qualifying accidents
4. Reasonable suspicion — based on trained supervisor observations
5. Return-to-duty — after a positive test before returning to duty
6. Follow-up — post-return-to-duty monitoring, minimum 6 tests in first 12 months, up to 60 months total

Cannabis Cutoffs and Confirmation

DOT uses the same cannabis cutoffs as SAMHSA:

• Initial screen: 50 ng/mL THC-COOH
• Confirmation: 15 ng/mL THC-COOH (GC-MS or LC-MS/MS)

Testing must be performed at a SAMHSA-certified laboratory.

Oral Fluid Testing — Authorized but Not Yet Operational

DOT authorized oral fluid (saliva) testing as an alternative to urine via a final rule effective December 5, 2024. However, the rule requires at least two HHS-certified oral fluid laboratories before the program can go operational. As of April 2026, zero labs have been certified. DOT oral fluid testing remains authorized but unavailable.

When operational, DOT oral fluid testing will use the SAMHSA Oral Fluid cutoffs (4 ng/mL screen, 2 ng/mL confirmation). This will dramatically shorten the effective detection window for cannabis — potentially reducing it from weeks to days.

The Medical Review Officer (MRO)

Every positive DOT drug test result goes to a Medical Review Officer (MRO), a licensed physician trained in drug testing interpretation. The MRO's role:

1. Review the lab result
2. Contact the employee to discuss any legitimate medical explanations
3. Verify the result as positive, negative, or cancelled based on the interview
4. Report the verified result to the employer

For cannabis, the MRO will ask about prescription medications that could explain the positive. A state medical cannabis card is not an acceptable medical explanation under DOT rules. Even if you have a valid prescription and are using cannabis legally under state law, the MRO is required by 49 CFR § 40.151(e) to verify the test as positive. See MRO Process.

The Substance Abuse Professional (SAP) Process

After a positive drug test, a DOT-regulated employee is removed from safety-sensitive duties immediately. To return to duty, they must:

1. Evaluation by a Substance Abuse Professional (SAP)
2. Complete recommended education/treatment
3. Follow-up evaluation by the SAP
4. Pass a return-to-duty test (directly observed)
5. Follow-up testing for minimum 12 months, up to 60 months

The employer is not required to reinstate the employee after completion of the SAP process. Return to safety-sensitive duties is a privilege, not a right.

Refusal to Test

Refusing a DOT drug test is treated the same as a positive result. Refusals include:

• Failing to appear for collection
• Leaving the collection site before the test is complete
• Providing a specimen that is out of range for temperature
• Providing a substituted or adulterated specimen
• Refusing directly observed collection when required
• Failing to cooperate with the collection procedures

All of these trigger the same consequences as a verified positive: removal from safety-sensitive duties, referral to a SAP, and the return-to-duty process.

Consequences of a DOT Positive

• Immediate removal from safety-sensitive duties
• Loss of DOT certification pending return-to-duty
• Permanent record in the FMCSA Drug & Alcohol Clearinghouse (for CDL drivers)
• Potential loss of employment (employers are not required to accommodate)
• SAP evaluation and treatment required before return
• Follow-up testing for years

The FMCSA Drug & Alcohol Clearinghouse

Since January 6, 2020, all CDL drug and alcohol test violations are reported to the FMCSA Clearinghouse. Employers are required to query the Clearinghouse before hiring a CDL driver and annually during employment. A cannabis violation in the Clearinghouse follows the driver for five years (or until return-to-duty process is completed).

Practical Reality for CDL Drivers

If you hold a CDL, the practical reality of DOT cannabis testing is:

• No state protection applies — not even in California, New York, or Colorado
• Medical cannabis cards provide zero protection
• Random testing means any day could be a test day
• Cannabis use off-duty during time off from driving can still result in a positive test days later
• A positive test is career-impacting, potentially career-ending
• The Clearinghouse makes moving to a different carrier to "start over" much harder

For CDL drivers and other DOT-regulated workers, the only safe approach is complete abstinence from cannabis.

Related Reading

• Federal Rules Overview
• SAMHSA Guidelines
• MRO Process
• Oral Fluid Testing